EP Patent

EP3250208B1 — 7-benzyl-4-(4-(trifluoromethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one and salts thereof and their use in therapy

Assigned to Oncoceutics Inc · Expires 2020-09-30 · 6y expired

What this patent protects

Patent listed against dordaviprone-hydrochloride.

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3250208B1
Jurisdiction: EP
Classification: —
Expires: 2020-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Oncoceutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.